Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response.
SELLAS Life Sciences Eyes Key Milestones for AML Therapies in 2025
SELLAS Life Sciences anticipates a pivotal 2025 with key clinical milestones for its hematologic malignancy therapies, including data readouts and regulatory feedback.
SELLAS Life Sciences' GPS Shows Promise in Phase 3 AML Trial, IDMC Recommends Continuation
The Independent Data Monitoring Committee (IDMC) recommended continuing SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).
SELLAS' SLS009 Shows Promise in Phase 2 AML Trial
SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, shows promising results in a Phase 2 trial for relapsed/refractory AML.
SELLAS' SLS009 Shows Promise in ASXL1-Mutated Solid Cancers
SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, demonstrates high efficacy in preclinical models of solid cancers with ASXL1 mutations.
T-Cell Malignancy Pipeline Shows Promise with Novel Therapies and Approvals
The T-cell malignancies market is experiencing growth driven by increased incidence, treatment advancements, and strategic biopharma partnerships.